Unlocking the potential of
genomic medicine

Investor FAQs

Show all
Aevi Genomic Medicine is a Delaware corporation with its corporate headquarters are located at 435 Devon Park Drive, Suite 715 in Wayne, Pennsylvania.
Aevi Genomic Medicine went public on April 2011.
The Company fiscal year ends on December 31st.
Aevi Genomic Medicine’s common stock trades on the NASDAQ Market under the ticker symbol “GNMX” and its CUSIP number is 00835P105.
Aevi Genomic Medicine does not currently pay any dividends.
Corporate Stock Transfer (CST) 3200 Cherry Creek Drive South, #430 Denver, CO, 80209 303-282-4800
For questions about your stock please contact our transfer agent, Corporate Stock Transfer (CST). 3200 Cherry Creek Drive South, #430 Denver, CO, 80209 303-282-4800

To change the address on your shareholder account you must send both your old and new addresses to our transfer agent, Corporate Stock Transfer (CST). 3200 Cherry Creek Drive South, #430 Denver, CO, 80209 303-282-4800

The Company does not have a direct stock purchase plan. Shares can be purchased through a stockbroker of your choice.
The auditor for Aevi Genomic Medicine is Ernst & Young LLP located in Philadelphia, Pennsylvania.
Legal counsel for Aevi Genomic Medicine is Pepper Hamilton LLP located in Philadelphia, Pennsylvania.
To find out more about Aevi Genomic Medicine visit our webpage at www.aevigenomics.com.
Aevi Genomic Medicines press release archive can be viewed under the “News Room” section under the “Investors” tab and financial reports are available under the “SEC Filings” section under the “Investors” tab located at our website www.aevigenomics.com.
Aevi Genomic Medicines’s SEC Filings can be found on www.sec.gov and are also available under the “SEC Filings” section under the “Investors” tab located at our website www.aevigenomics.com.
For a list of the Senior Management team and the Board of Directors please visit the “Company” tab of our website.
You can submit inquiries to Aevi Genomic Medicines’ investor relations department by contacting investors@aevigenomics.com or by contacting: Christopher F. Brinzey Westwicke Partners EMAIL: chris.brinzey@westwicke.com PHONE: 339-970-2843